candesartan has been researched along with Nasopharyngeal Neoplasms in 1 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Nasopharyngeal Neoplasms: Tumors or cancer of the NASOPHARYNX.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, H | 1 |
| Cai, Y | 1 |
| Feng, Q | 1 |
| Wang, X | 1 |
| Tian, W | 1 |
| Qiu, S | 1 |
| Wang, Y | 1 |
| Li, Z | 1 |
| Wu, J | 1 |
1 other study available for candesartan and Nasopharyngeal Neoplasms
| Article | Year |
|---|---|
Ultrasound-Stimulated Microbubbles Enhance Radiosensitization of Nasopharyngeal Carcinoma.
Topics: Angiotensin II; Animals; Antigens, CD34; Benzimidazoles; Biphenyl Compounds; Carcinoma; Cell Line, T | 2018 |